StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock analysis

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/308% above fair value
$433.03+0.43 (+0.10%)

Close on Nov 11, 2026Market cap $10.00BP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance2Health2Dividend0

Weak5 of 30 checks passed

Madrigal Pharmaceuticals passes 5 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
2/6
Financial health
2/6
Dividend
0/6

What stands out

  • Low bankruptcy risk

    The Altman Z-score is 6.78; above 3 is the safe zone and below 1.8 the distress zone.

  • Growing faster than the industry

    Revenue grew 149% over the last twelve months; the Drugs median is 8.0%.

  • Return on equity above the industry

    Madrigal Pharmaceuticals's return on equity of -53.3% is above the Drugs median of -58.9%.

  • Net margin above the industry

    Madrigal Pharmaceuticals's net margin of -25.3% is above the Drugs median of -53.0%.

What to watch

  • Margin of safety under 20%

    The price is 7.6% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $433.03 is above our fair value estimate of $402.51.

  • Return on equity under 15%

    Return on equity was -53.3% over the last twelve months and averaged -102% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -1338%, below the 10% that usually covers the cost of capital.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Madrigal Pharmaceuticals's price-to-book of 19.10 is above the Drugs median of 2.29.

  • Trading above fair value

    The share price of $433.03 is above our fair value estimate of $402.51.

  • Margin of safety under 20%

    The price is 7.6% above fair value, so there is no margin of safety.

Growth1/6

  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 149% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -53.3% over the last twelve months and averaged -102% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -1338%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Madrigal Pharmaceuticals's return on equity of -53.3% is above the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin above the industry

    Madrigal Pharmaceuticals's net margin of -25.3% is above the Drugs median of -53.0%.

Financial health2/6

  • High debt

    Debt is 65.1% of shareholders' equity, above the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -58.0% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -10.2 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 3.20 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 6.78; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Madrigal Pharmaceuticals has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$402.51

The share price is 8% above this estimate.

20%+ below
Near fair value
20%+ above
$433.03Price
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B7.8×13.6×2.3×$176.6850%
P/S11.3×18.1×4.8×$628.3550%
Fair value$402.51100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 13.6
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$209.56M
Value traded per 1% price move
$97.31M

Downside

Medium risk

Typical loss in a bad month
17.7%
Volatility (annualized)
44%
Sharpe ratio, 1 year
-0.39
Beta to the S&P 500 (5Y)
0.73

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Operating margin

-31.3%

Net margin

-30.1%

See a number that looks wrong?